Reaktionsgleichung
Cl[C:2]1[CH:3]=[CH:4][C:5]([N+:15]([O-:17])=[O:16])=[C:6]([N:8]2[CH2:13][CH2:12][CH:11]([CH3:14])[CH2:10][CH2:9]2)[CH:7]=1.[OH:18][CH2:19][CH2:20][N:21]1[CH2:26][CH2:25][NH:24][CH2:23][CH2:22]1>>[CH3:14][CH:11]1[CH2:12][CH2:13][N:8]([C:6]2[CH:7]=[C:2]([N:24]3[CH2:25][CH2:26][N:21]([CH2:20][CH2:19][OH:18])[CH2:22][CH2:23]3)[CH:3]=[CH:4][C:5]=2[N+:15]([O-:17])=[O:16])[CH2:9][CH2:10]1Komponenten
3
Versuchsvorschrift
The procedure of Example 4, step (b) was followed using 810 mg (3.18 mmol) of 1-(5-chloro-2-nitro-phenyl)-4-methyl-piperidine (as prepared in the Example 12, step (a)) and 1.95 mL (15.9 mmol) of 1-(2-hydroxyethyl)piperazine for 14 h to afford 1.11 g (100%) of the title compound as a yellow solid: Mass spectrum (ESI, m/z): Calcd. for C18H28N4O3, 349.2 (M+H), found 349.2.
Quellen und Nachweise
- ORD-Eintrag
- ord-d82e1530348b4c69824501f2e7659a9a
- Quelldatensatz
- uspto-grants-2010_04
- Patentnummer
- US07705042B2
Verknüpfte Notizen
Wird geladen…